Leonard S. Schleifer - 11 Jun 2024 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role
Bd. Co-Chair, President & CEO, Director
Signature
/s/**Leonard S. Schleifer
Issuer symbol
REGN
Transactions as of
11 Jun 2024
Net transactions value
-$25,610,229
Form type
4
Filing time
13 Jun 2024, 16:01:19 UTC
Previous filing
10 Jun 2024
Next filing
11 Dec 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock Sale $7,432,865 -7,321 -11% $1015.28 56,877 11 Jun 2024 By Trust F1, F2
transaction REGN Common Stock Sale $1,770,958 -1,743 -3.1% $1016.04 55,134 11 Jun 2024 By Trust F1, F3
transaction REGN Common Stock Sale $15,106,649 -14,879 -27% $1015.30 40,255 12 Jun 2024 By Trust F1, F4
transaction REGN Common Stock Sale $274,487 -270 -0.67% $1016.62 39,985 12 Jun 2024 By Trust F1, F5
transaction REGN Common Stock Conversion of derivative security $0 +1,000 $0.000000 1,000 12 Jun 2024 by Trust for Son F1
transaction REGN Common Stock Sale $1,025,270 -1,000 -100% $1025.27 0 12 Jun 2024 by Trust for Son F1, F6
holding REGN Common Stock 157,552 11 Jun 2024 2023 GRAT
holding REGN Common Stock 5,932 11 Jun 2024 By 401(k) Plan
holding REGN Common Stock 466,877 11 Jun 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction REGN Class A Stock Conversion of derivative security $0 -1,000 -6.3% $0.000000 14,775 12 Jun 2024 Common Stock 1,000 $0.000000 by Trust for Son F1, F7, F8
holding REGN Class A Stock 1,710,790 11 Jun 2024 Common Stock 1,710,790 $0.000000 Direct F7, F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 5, 2024.
F2 Represents volume-weighted average price of sales of 7,321 shares of common stock of Regeneron Pharmaceuticals, Inc. (the "Company") on June 11, 2024 at prices ranging from $1,015.00 to $1,015.85. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 11, 2024 at each separate price.
F3 Represents volume-weighted average price of sales of 1,743 shares of Company stock on June 11, 2024 at prices ranging from $1,016.04 to $1,016.10. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 11, 2024 at each separate price.
F4 Represents volume-weighted average price of sales of 14,879 shares of Company stock on June 12, 2024 at prices ranging from $1,015.00 to $1,015.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 12, 2024 at each separate price.
F5 Represents volume-weighted average price of sales of 270 shares of Company stock on June 12, 2024 at prices ranging from $1,016.10 to $1,016.80. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 12, 2024 at each separate price.
F6 Represents volume-weighted average price of sales of 1,000 shares of Company stock on June 12, 2024 at prices ranging from $1,025.00 to $1,025.55. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 12, 2024 at each separate price.
F7 Class A Stock of the Company converts to common stock of the Company on a one-to-one basis upon certain events or upon election of the shareholder.
F8 These shares of Class A Stock are presently convertible and such conversion feature does not expire.